Botensilimab
- Generic Name
- Botensilimab
- Drug Type
- Biotech
- CAS Number
- 2408310-37-0
- Unique Ingredient Identifier
- 1Z5YC3ME5N
- Background
Botensilimab is under investigation in clinical trial NCT03860272 (Fc-engineered Anti-ctla-4 Monoclonal Antibody in Advanced Cancer).
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
- Conditions
- Microsatellite Stable Rectal CarcinomaLocally Advanced Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06843434
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
- Conditions
- Metastatic Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Benjamin Spieler
- Target Recruit Count
- 20
- Registration Number
- NCT06843551
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
- Conditions
- Rectal AdenocarcinomaStage IIA Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Digital Rectal ExaminationProcedure: Endoscopic BiopsyProcedure: Magnetic Resonance ImagingRadiation: Radiation TherapyProcedure: Sigmoidoscopy
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT06780787
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
- Conditions
- Colorectal Cancer (CRC)Pancreatic CancerNon-Small Cell Lung Cancer (NSCLC)Hepatocellular Carcinoma (HCC)MelanomaSarcomaOvarian CancerProstate Cancer
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT06751524
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
- Conditions
- Stage IV Colorectal Cancer AJCC v8Advanced Colon AdenocarcinomaStage IV Colon Cancer AJCC v8Advanced Colorectal AdenocarcinomaMetastatic Colorectal AdenocarcinomaAdvanced Rectal AdenocarcinomaMetastatic Colon AdenocarcinomaStage III Colon Cancer AJCC v8Stage IV Rectal Cancer AJCC v8Metastatic Rectal Adenocarcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 84
- Registration Number
- NCT06575725
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
- Conditions
- Pancreatic CancerColorectal Cancer
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 54
- Registration Number
- NCT06411691
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
- Conditions
- Gastric CancerMSI-HMetastatic CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 124
- Registration Number
- NCT06346197
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal AdenocarcinomaStage IV Colorectal Cancer AJCC V8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyOther: Dietary InterventionProcedure: Magnetic Resonance ImagingDietary Supplement: Vitamin C
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 15
- Registration Number
- NCT06336902
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Immune Oncology Research Institute
- Target Recruit Count
- 45
- Registration Number
- NCT06322108
- Locations
- 🇦🇲
Hematology Center named after prof. R. Yeolyan, Yerevan, Armenia
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
- Conditions
- Liver MetastasesColorectal CancerColorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 24
- Registration Number
- NCT06300463
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.